Document is current
Any future updates will be listed below
-
Authors
Mori, Yuriko https://orcid.org/0000-0001-5666-0559
Tamburini, Katharina
Novruzov, Emil
Schmitt, Dominik
Mavriopoulou, Eleni
Loosen, Sven H.
Roderburg, Christoph
Watabe, Tadashi
Kratochwil, Clemens
Röhrich, Manuel
Alavi, Abass
Haberkorn, Uwe
Giesel, Frederik L.
-
Funding
Funding for this research was provided by:
Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
- License Information
-
More Information
Article History
Received: 27 October 2024
Accepted: 12 February 2025
First Online: 6 March 2025
Declarations
:
: FLG has a patent application for quinolone-based FAP-targeting agents for imaging and therapy in nuclear medicine and shares a consultancy group for iTheranostics. FLG is also an advisor at ABX, Telix, Alpha Fusion and SOFIE Biosciences. C.K. Royalties from SOFIE Biosciences and iTheranostics; patents for FAP inhibitors; participates on advisory board on neuroendocrine tumors for Advanced Accelerator Applications Germany, a Novartis company; stock or stock options in FAPi-Holding. U.H. Royalties from iTheranostics and SOFIE Biosciences; patent for FAPI tracers licensed to SOFIE Biosciences. The other authors declare no conflict of interest regarding this manuscript.
: All procedures performed in studies involving human participants were approved by regional ethics committee board (approval S358/2022) and carried out in accordance with the ethical standards of the institutional and/or national research committees and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
